An immunofluorescence assay (IFA) for the detection of immunoglobulin G antibodies directed against Helicobacter pylori was evaluated by comparing 20 serum specimens from patients with a positive urease test on biopsy material and 20 serum specimens from patients with a negative test and with defined clinical symptoms. The resulting anti-H. pylori titers were classified as follows: negative, c64; borderline, 128; and positive, .256. By using these criteria, the IFA was subsequently tested, using 100 serum specimens from patients with gastric complaints. Overall, the titers were 71% positive, 10% borderline, and 19% negative.
experiments demonstrated that possible cross-reactivity between H. pyloni and C. jejuni did not influence serodiagnosis.
Warren and Marshall (30) first described the association between infection with Campylobacter pylori, now renamed Helicobacter pylori (8) , and the presence of type B gastritis or peptic ulcer disease. Subsequently, there has been controversy about the etiologic role of this organism in gastrointestinal disease. Recent studies have demonstrated that H. pylori infections induce pathogenic gastrointestinal effects in gnotobiotic piglets (13, 15) , as well as type B gastritis in humans. The latter association was described by Marshall (17) and Morris (20) after ingestion of an H. pylori strain. As previously reported (4, 24) , a highly significant correlation exists between the activity of gastritis and the grade of H. pylori colonization. Therefore, H. pylori was considered to cause type B gastritis, but its role in peptic ulceration remains less clear (2, 4, 5, 7, 22) . There is continuing uncertainty concerning the mechanism of pathogenicity and the reasons for this organism's predilection for the colonization of gastric mucosa.
At the present time, the diagnosis of infections with H. pylori is mainly based on direct microscopy and culture from gastric biopsy specimens after endoscopy or on indirect methods based on urease activity such as the [13C]- or [14C]urea breath test or the CLO test (1, 10, 11, 18, 25) . In contrast to these invasive and technically demanding diagnostic procedures, the specific detection of serum antibodies directed against H. pylori would be a sensitive and relatively simple tool for the evaluation of suspected infections (11, 22 fixation methods (2, 5, 9, 22, (27) (28) (29) , which may replace direct methods when endoscopy is contraindicated, have been described. In this paper, an indirect immunofluorescence assay (IFA) is described which could be employed routinely for the detection of immunoglobulin G (IgG) antibodies directed against H. pylori. Possible cross-reactivity with Campylobacter jejuni was evaluated to assess the specificity of the IFA results. well) was applied (diluted 1:50 in PBS plus 2% fetal calf serum) and incubated at 37°C for 30 min. The second-stage washing, rinsing, dipping, and drying steps were carried out as described above. A small drop of mounting fluid (PBS diluted 10:1 in glycerol) was placed in each well, and the slides were subsequently covered with glass cover slips and microscopically examined.
MATERIALS AND METHODS
The fluorescence of the bacterial cells was visualized at 400-fold magnification with a fluorescence microscope (IM-405; Zeiss, Oberkochen, Federal Republic of Germany). The titer of IgG antibodies directed against H. pylori was determined by the reciprocal of the highest dilution of serum at which a 3+ bright, apple-green staining could be detected.
Origin of serum specimens. The IFA presented herein was evaluated by ascertaining titers of serum specimens from 20 patients with positive biopsy urease tests (CLO test; Heipha, Heidelberg, Federal Republic of Germany) in the presence of gastric or duodenal ulcers (group la). These patients would be seropositive unless they failed to generate an immunological response because the CLO test is 100% specific (1, 3, 25, 26) . For controls, 20 serum samples from patients undergoing at least 5 CLO test-negative antral biopsies and exhibiting neither active antral gastritis nor peptic ulcerations (group lb), which should therefore be seronegative to H. pylori, were also examined by IFA.
The diagnostic utility of the test criteria was validated by determining 100 titers in patients with clinical gastrointestinal illness who all underwent gastroscopy and CLO tests (group 2). Group 2 patients were further separated into three clinical syndromes: gastritis (group 2a), duodenal ulcer (group 2b), and gastric ulcer (group 2c).
Cross-reactivity between H. pylori and C. jejuni was tested by determining the H. pylori IFA titers of 50 patients with positive or borderline IgG antibody reaction to C. jejuni as previously determined by complement fixation. Additionally, the C. jejuni complement fixation titers of 50 H. pylori IFA-positive or borderline sera were determined.
Complement fixation tests. 
RESULTS
The morphology of H. pylori cells at 1,000-fold magnification under a fluorescence microscope is shown in Fig. 1 . Fluorescence-labeled bacteria appeared as curved, rodshaped cells with two to three coils. Coccoid reduction forms were detected only rarely, and no flagella were seen by using these experimental methods. Gel electrophoretic analysis of the outer membrane proteins demonstrated that H. pylori ERI 1 is antigenically highly similar to H. pylori type strain NCTC 11637 (Fig. 2) .
Under the present conditions, in the group of patients (group 1) with a positive biopsy urease test result, 3 serum specimens (15%) with a titer of 128, 11 serum specimens (55%) with a titer of 256, 5 serum specimens (25%) with a titer of 512, and 1 serum specimen (5%) with a titer of .1,024 were found. Similarly, in patients with a negative biopsy urease test result, 11 serum specimens (55%) exhibited a titer of c32, 5 serum specimens (25%) exhibited a titer of 64, and 4 serum samples (20%) exhibited a titer of 128. Because of an overlapping in both reference groups at a serum titration endpoint of 128, negative titers were defined to be c64, whereas a titer of 128 was considered to be borderline and titers of .256 were considered presumptive evidence of an H. pylori infection at an undetermined time in the past.
The distribution of negative, borderline, and positive sera within the three different clinical groups is depicted in Fig. 3 . Overall, group 2 produced 71% positive and 10% borderline titers, whereas within group 2a 74% were positive and 10% had borderline results. In group 2b, the greatest number of positive titers was observed, with 84% positive and 4% samples known to be positive or borderline for C. jejuni, 28% were positive, 10% were borderline, and 62% were negative. When C. jejuni titers were measured for known H. pylori-positive or borderline serum samples, 2% were positive, 4% were borderline, and 94% were negative (Table 1) . After absorption experiments were performed, no H. pyloripositive and only 4% borderline results could be obtained among C. jejuni-positive or borderline sera, while neither positive nor borderline results were found when determining C. jejuni titers of H. pylori-positive or borderline sera. These findings support the view that all examined H. pylori IFA and C. jejuni complement fixation test-positive patients were infected with both C. jejuni and H. pylori, rather than indicating cross-reactivity. Table 2 illustrates the serologic changes that may ensue when complete eradication of H. pylori is achieved after treatment with colloidal bismuth subcitrate over a period of 4 weeks and erythromycin for the final 2 weeks. A slight, but measurable decrease of the anti-H. pylori IgG titer occurred 6 months after therapy, whereas a significant drop of values could be found within 9 to 12 months after successful 
